Categorized | Melanoma In The News, FDA

FDA accepts application for binimetinib-encorafenib combination for BRAF-mutated melanoma

Source: Healio, September 2017

The FDA accepted for review new drug applications that seek the use of the COMBO450 regimen to treat patients with BRAF-mutant advanced, unresectable or metastatic melanoma, according to the drugs’ manufacturer.

COMBO450 is comprised of binimetinib (MEK162, Array BioPharma), an oral small molecule MEK inhibitor, and encorafenib (LGX818, Array BioPharma), a novel oral small molecule BRAF inhibitor.

The application included data from the pivotal phase 3 COLUMBUS trial, designed to make three comparisons — COMBO450 vs. monotherapy with the BRAF inhibitor vemurafenib (Zelboraf, Genentech); COMBO450 vs. encorafenib alone; and encorafenib monotherapy vs. vemurafenib monotherapy — for patients with BRAF-mutant advanced, unresectable or metastatic melanoma. Patients assigned the COMBO450 regimen received 45 mg binimetinib twice daily and 450 mg encorafenib once daily.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories